InMed Pharmaceuticals Inc
NASDAQ:INM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Haima Automobile Co Ltd
SZSE:000572
|
CN |
|
Mediaalpha Inc
NYSE:MAX
|
US |
InMed Pharmaceuticals Inc
Total Equity
InMed Pharmaceuticals Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
InMed Pharmaceuticals Inc
NASDAQ:INM
|
Total Equity
$9.6m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
5%
|
CAGR 10-Years
30%
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Total Equity
-$554m
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Canopy Growth Corp
TSX:WEED
|
Total Equity
CA$758.2m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
19%
|
|
|
Cronos Group Inc
TSX:CRON
|
Total Equity
$1.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
63%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Total Equity
$130.6m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
46%
|
CAGR 10-Years
84%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Total Equity
CA$767.3m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
InMed Pharmaceuticals Inc
Glance View
InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2001-06-21. The firm is developing a pipeline of prescription-based products targeting treatments for diseases with unmet medical needs as well as developing manufacturing technologies. The company is specializing in the research and development of cannabinoid-based therapies and a system for the manufacturing of pharmaceutical-grade cannabinoids. The company is also developing an integrated biosynthesis-based manufacturing approach, called IntegraSyn, for synthesizing pharmaceutical-grade cannabinoids, for potential use in product candidates. The firm's two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 provides direct neuroprotection and reduce intraocular pressure in the eye.
See Also
What is InMed Pharmaceuticals Inc's Total Equity?
Total Equity
9.6m
USD
Based on the financial report for Dec 31, 2025, InMed Pharmaceuticals Inc's Total Equity amounts to 9.6m USD.
What is InMed Pharmaceuticals Inc's Total Equity growth rate?
Total Equity CAGR 10Y
30%
Over the last year, the Total Equity growth was 55%. The average annual Total Equity growth rates for InMed Pharmaceuticals Inc have been -13% over the past three years , 5% over the past five years , and 30% over the past ten years .
